Followers | 4 |
Posts | 243 |
Boards Moderated | 0 |
Alias Born | 05/31/2008 |
![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Thursday, September 22, 2011 6:38:39 PM
It's really quite logical. The warrant holders, like many others, have been loyal stockholders since the very beginning. The difference between them and people who bought on the open market is that they tied up large amounts of money (up to $500K) for a year and did so when there was a very small difference between the stock price and the offering price. And they did this years ago when we weren't nearly as far along as we are now. Many of these original investors doubled down when we needed more money and they're still holding onto all of their stock. People who bought on the open market had the ability to quickly get out if they felt the need to do so. These warrant holders were tied up for a year (since changed to 6 months)
We may need a small amount of money in the future in order to bring more drugs into the FDA. I can go to these people. They're not the typical sleazy Wall Street financial people who short your stock when you're in discussions with them about raising additional capital. I get at least one offer a day from people who want to give us money. I've turned down everyone.
Some of the holders may never exercise their warrants. If they do, they have to hold the restricted stock for 6 months. Also, the number of warrants is small compared to the total number of shares currently out there.
So, as far as I'm concerned, all of the benefit accrues to the Company, we've remained loyal to those investors who remained loyal to us, there's minimal dilution if and when they exercise and we have a loyal financing source in people who don't play the Wall Street games. What could be better than that?
Make sense?
Sincerely,
PS You have my permission to post this reply
EUGENE SEYMOUR, MD, MPH
Chief Executive Officer
NANOVIRICIDES, INC
Nanotechnology-based targeted anti-viral therapeutics
http://www.nanoviricides.com
eugene@nanoviricides.com
310-486-5677
Recent NNVC News
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
- Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs • InvestorsHub NewsWire • 07/06/2023 03:16:37 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM